Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shao-Lai Zhou

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Hepatology (Baltimore, Md.)|May 27, 2016
ReplyShao-Lai Zhou, Jian Zhou
Clinical and Molecular Hepatology|November 11, 2024
Correspondence to editorial on "Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma"Yu-Hang Ye, Shao-Lai Zhou
Clinical and Molecular Hepatology|February 26, 2025
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma"Rong-Qi Sun, Shao-Lai Zhou
Cancer Immunology, Immunotherapy : CII|June 16, 2019
Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resectionZheng-Jun Zhou, Hao-Yang Xin, Jia Li, et al.
Journal of Cancer|October 5, 2016
Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular CarcinomaAo Huang, Xin Zhang, Shao-Lai Zhou, et al.
Journal of Cancer|October 5, 2016
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral HeterogeneityAo Huang, Xin Zhang, Shao-Lai Zhou, et al.
Cancer Cell International|December 9, 2020
Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resectionZhi-Qiang Hu, Zheng-Jun Zhou, Chu-Bin Luo, et al.
Future Oncology (London, England)|January 11, 2018
Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosisPeng-Cheng Wang, Zhi-Qiang Hu, Shao-Lai Zhou, et al.
Cancer Immunology, Immunotherapy : CII|August 8, 2020
Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinomaZhi-Qiang Hu, Hao-Yang Xin, Chu-Bin Luo, et al.
NPJ Genomic Medicine|April 8, 2020
MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signalingZheng-Jun Zhou, Chu-Bin Luo, Hao-Yang Xin, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Hepatology (Baltimore, Md.)|May 27, 2016
ReplyShao-Lai Zhou, Jian Zhou
Clinical and Molecular Hepatology|November 11, 2024
Correspondence to editorial on "Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma"Yu-Hang Ye, Shao-Lai Zhou
Clinical and Molecular Hepatology|February 26, 2025
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma"Rong-Qi Sun, Shao-Lai Zhou
Cancer Immunology, Immunotherapy : CII|June 16, 2019
Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resectionZheng-Jun Zhou, Hao-Yang Xin, Jia Li, et al.
Journal of Cancer|October 5, 2016
Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular CarcinomaAo Huang, Xin Zhang, Shao-Lai Zhou, et al.
Journal of Cancer|October 5, 2016
Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral HeterogeneityAo Huang, Xin Zhang, Shao-Lai Zhou, et al.
Cancer Cell International|December 9, 2020
Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resectionZhi-Qiang Hu, Zheng-Jun Zhou, Chu-Bin Luo, et al.
Future Oncology (London, England)|January 11, 2018
Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosisPeng-Cheng Wang, Zhi-Qiang Hu, Shao-Lai Zhou, et al.
Cancer Immunology, Immunotherapy : CII|August 8, 2020
Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinomaZhi-Qiang Hu, Hao-Yang Xin, Chu-Bin Luo, et al.
NPJ Genomic Medicine|April 8, 2020
MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3β/β-catenin signalingZheng-Jun Zhou, Chu-Bin Luo, Hao-Yang Xin, et al.
Pageof 5